Results 221 to 230 of about 137,923 (290)

Risk of cancer among individuals with a history of bacterial sexually transmitted infections: A population‐based study in Alberta, Canada

International Journal of Cancer, Volume 158, Issue 5, Page 1383-1395, 1 March 2026.
What's New? While previous studies have identified the carcinogenicity of viral agents such as HIV, the role of bacterial sexually transmitted infections in carcinogenesis remains understudied despite them similarly causing chronic inflammation.
Hina M. Qureshi, Taylor Hughes, Eduardo L. Franco, Kirsten M. Fiest, Jennifer Gratrix, Petra A. Smyczek, Ronald Read, Arfan R. Afzal, Rob Deardon, Aliya Kassam, Miranda M. Fidler‐Benaoudia   +10 more
wiley   +1 more source

Thrombotic complications of central venous catheterization with peripherally inserted catheters in patients with classical-Hodgkin lymphoma. [PDF]

Hemasphere
Picardi M, Giordano C, Vincenzi A, Scarpa A, Pugliese N, Della Pepa R, Pane F.   +6 more
europepmc   +1 more source

Considerations for Menstrual Suppression in Patients With Hematologic Malignancies

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.
ABSTRACT Patients who menstruate during treatment for hematologic malignancies have a higher risk of heavy vaginal bleeding due to thrombocytopenia caused by malignancy and myelosuppressive chemotherapy. Heavy menstrual bleeding is associated with significant morbidity in this patient population, and menstrual suppression is a standard of supportive ...
Sahaana Veeravalli, Allison Schepers, Lydia L. Benitez, Martina S. Fraga   +3 more
wiley   +1 more source

Ocular Involvement of Relapsed Nodal T Follicular Helper Cell Lymphoma, Angioimmunoblastic Type. [PDF]

EJHaem
Bamba S, Nishikubo M, Ito SI, Yamakawa J, Hara S, Yamamoto R.   +5 more
europepmc   +1 more source

Overall Good Quality of Life Reported by Survivors of Childhood Hodgkin Lymphoma in Sweden and Finland

Acta Paediatrica, Volume 115, Issue 3, Page 697-705, March 2026.
ABSTRACT Aim Most children with Hodgkin lymphoma (HL) survive today, yet about 50% experience long‐term complications. This study evaluated health‐related quality of life (HRQoL) in survivors of childhood HL. Methods Two different HRQoL‐instruments, the EuroQoL 5‐Dimension 5‐Level (EQ‐5D‐5L) and Patient‐Reported Outcomes Measurement Information System (
Mia Giertz, Annika Englund, Fanny Fernsten, Sascha Michelsen Wilk, Riitta Niinimäki, Arja Harila, Henri Aarnivala   +6 more
wiley   +1 more source

HERV-K Envelope Induce a Humoral Response in Non-Hodgkin Lymphoma Patients. [PDF]

Curr Microbiol
Cossu I, Ruberto S, Filippi E, Simula ER, Noli M, Mottula A, Fozza C, Sechi LA.   +7 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Prognostic implication of serum levels of IL-6 and IL-10 in children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma. [PDF]

BMC Cancer
Zeng C, Wei Z, Huang J, Zhu J, Sun F, Wang J, Lu S, Zhang Y, Sun X, Zhen Z.   +9 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source